| Filing date | Form | Description | Filing Group | View |
|---|---|---|---|---|
| D | Notice of Exempt Offering of Securities |
Other
|
||
| 8-K | Report of unscheduled material events or corporate event |
Current Reports
|
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA | |
| 8-K | Report of unscheduled material events or corporate event |
Current Reports
|
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA | |
| 3 | Initial filing by director officer or owner of more than ten percent |
3,4,5
|
||
| 3 | Initial filing by director officer or owner of more than ten percent |
3,4,5
|
||
| 3 | Initial filing by director officer or owner of more than ten percent |
3,4,5
|
||
| 3 | Initial filing by director officer or owner of more than ten percent |
3,4,5
|
||
| 3 | Initial filing by director officer or owner of more than ten percent |
3,4,5
|
||
| 3 | Initial filing by director officer or owner of more than ten percent |
3,4,5
|
||
| 3 | Initial filing by director officer or owner of more than ten percent |
3,4,5
|
Data provided by Kaleidoscope.
GNI Group, Ltd. (2160:Tokyo) (“GNI Japan”) holds an indirect, controlling interest in Gyre Therapeutics, Inc. From time to time, GNI Japan will disclose historical and forward looking information, which will include information about our business. We may not have previously disclosed such information. Please refer to https://www.gnipharma.com/ir/yuho/ for GNI Japan’s Investor Information and Securities Reports.
